Latest filings (excl ownership)
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3 Apr 24
8-K
Entry into a Material Definitive Agreement
18 Mar 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
1 Mar 24
10-Q
2024 Q1
Quarterly report
20 Feb 24
NT 10-Q
Notice of late quarterly filing
15 Feb 24
10-K
2023 FY
Annual report
14 Feb 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
7 Feb 24
8-K
Changes in Registrant's Certifying Accountant
12 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
NT 10-K
Notice of late annual filing
29 Dec 23
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
15 Dec 23
8-K
Departure of Directors or Certain Officers
8 Dec 23
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
5 Dec 23
8-K
Entry into a Material Definitive Agreement
22 Nov 23
8-K
Entry into a Material Definitive Agreement
15 Nov 23
8-K
Other Events
9 Nov 23
S-1/A
IPO registration (amended)
8 Nov 23
S-1/A
IPO registration (amended)
5 Oct 23
8-K
Entry into a Material Definitive Agreement
4 Oct 23
8-K
Material Modifications to Rights of Security Holders
27 Sep 23
8-K
Arch Therapeutics Provides AC5® Commercialization Update
13 Sep 23
8-K
Entry into a Material Definitive Agreement
7 Sep 23
8-K
Entry into a Material Definitive Agreement
6 Sep 23
DEF 14C
Information statement
1 Sep 23
8-K
Departure of Directors or Certain Officers
23 Aug 23
PRE 14C
Preliminary information
22 Aug 23
10-Q
2023 Q3
Quarterly report
11 Aug 23
8-K
Entry into a Material Definitive Agreement
4 Aug 23
8-K
Departure of Directors or Certain Officers
24 Jul 23
8-K
Entry into a Material Definitive Agreement
13 Jul 23
8-K
Entry into a Material Definitive Agreement
7 Jul 23
8-K
Entry into a Material Definitive Agreement
22 Jun 23
10-Q
2023 Q2
Quarterly report
22 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
8-K
Entry into a Material Definitive Agreement
20 Apr 23
8-K
Entry into a Material Definitive Agreement
16 Mar 23
8-K
Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services
9 Mar 23
8-K
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities
7 Mar 23
8-K
Entry into a Material Definitive Agreement
15 Feb 23
Latest ownership filings
SC 13G/A
Parker Michael Andrew
22 Jan 24
4
MICHAEL S ABRAMS
8 Sep 23
4
Terrence W Norchi
8 Sep 23
4
Laurence Hicks
8 Sep 23
SC 13G
Stahl Andrew
9 Aug 23
SC 13G
wilson brandt
25 Jul 23
SC 13G
BIGGER CAPITAL FUND L P
14 Jul 23
SC 13G
Oasis Capital, LLC
12 Jul 23
SC 13G/A
Parker Michael Andrew
27 Jan 23
SC 13G/A
Parker Michael Andrew
25 Jan 23
4
PUNIT DHILLON
10 Nov 22
4
Guy L. Fish
10 Nov 22
4
Laurence Hicks
10 Nov 22
4
Dan Yrigoyen
10 Nov 22
4
Terrence W Norchi
10 Nov 22
4
MICHAEL S ABRAMS
10 Nov 22
4
MICHAEL S ABRAMS
8 Jul 22
4
Terrence W Norchi
8 Jul 22
4
Laurence Hicks
8 Jul 22
4
Dan Yrigoyen
9 Jun 22
SC 13G/A
Parker Michael Andrew
12 Jan 22
4
Guy L. Fish
4 Jan 22
3
Guy L. Fish
4 Jan 22
4
Laurence Hicks
13 Oct 21
3
Laurence Hicks
12 Oct 21
4
Dan Yrigoyen
1 Oct 21
4
MICHAEL S ABRAMS
1 Oct 21
4
JAMES R SULAT
1 Oct 21
4
PUNIT DHILLON
1 Oct 21
4
Terrence W Norchi
1 Oct 21
4
Dan Yrigoyen
11 Aug 21
3
Dan Yrigoyen
11 Aug 21
3
MICHAEL S ABRAMS
10 May 21
SC 13G/A
Parker Michael Andrew
22 Jan 21
4
JAMES R SULAT
23 Jun 20
SC 13G/A
Beneficial ownership report (amended)
23 Jan 20
4
Terrence W Norchi
23 Dec 19
4
RICHARD E DAVIS
23 Dec 19
4
JAMES R SULAT
23 Dec 19
4
PUNIT DHILLON
23 Dec 19